JP2006518197A5 - - Google Patents

Download PDF

Info

Publication number
JP2006518197A5
JP2006518197A5 JP2006501525A JP2006501525A JP2006518197A5 JP 2006518197 A5 JP2006518197 A5 JP 2006518197A5 JP 2006501525 A JP2006501525 A JP 2006501525A JP 2006501525 A JP2006501525 A JP 2006501525A JP 2006518197 A5 JP2006518197 A5 JP 2006518197A5
Authority
JP
Japan
Prior art keywords
compound
compound according
lna
ras
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006501525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518197A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2004/000097 external-priority patent/WO2004069992A2/en
Publication of JP2006518197A publication Critical patent/JP2006518197A/ja
Publication of JP2006518197A5 publication Critical patent/JP2006518197A5/ja
Withdrawn legal-status Critical Current

Links

JP2006501525A 2003-02-10 2004-02-10 ラス発現の改変のためのオリゴマー化合物 Withdrawn JP2006518197A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300184 2003-02-10
DKPA200301539 2003-10-20
PCT/DK2004/000097 WO2004069992A2 (en) 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of ras expression

Publications (2)

Publication Number Publication Date
JP2006518197A JP2006518197A (ja) 2006-08-10
JP2006518197A5 true JP2006518197A5 (cg-RX-API-DMAC7.html) 2007-03-22

Family

ID=32852146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006501525A Withdrawn JP2006518197A (ja) 2003-02-10 2004-02-10 ラス発現の改変のためのオリゴマー化合物

Country Status (6)

Country Link
US (2) US20040248840A1 (cg-RX-API-DMAC7.html)
EP (1) EP1592795A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006518197A (cg-RX-API-DMAC7.html)
AU (1) AU2004209599A1 (cg-RX-API-DMAC7.html)
CA (1) CA2515644A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004069992A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649817T3 (es) 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
US20040241717A1 (en) * 2003-02-10 2004-12-02 Santaris Pharma A/S Oligomeric compounds for the modulation of thioredoxin expression
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
EP1824975B9 (en) * 2004-11-09 2011-04-20 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
BRPI0515726A8 (pt) 2004-11-09 2017-09-12 Santaris Pharma As Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US20060234277A1 (en) * 2005-03-31 2006-10-19 Amgen Inc. Method for selectively blocking hemoglobin RNA amplification
WO2007068113A1 (en) * 2005-12-16 2007-06-21 Mcgill University 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof
CA3042781C (en) * 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
AU2007323469B2 (en) * 2006-11-23 2014-07-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligonucleotides for modulating target RNA activity
EP2001188A1 (en) * 2007-06-08 2008-12-10 F.Hoffmann-La Roche Ag Method for authenticating a medical device and a remote device
CN101821722A (zh) * 2007-06-29 2010-09-01 霍夫曼-拉罗奇有限公司 用于优化在医疗装置和远程电子装置之间的通信的装置和方法
ES2715277T3 (es) * 2007-06-29 2019-06-03 Hoffmann La Roche Aparato y método para controlar de manera remota un dispositivo médico ambulatorio
JP5723154B2 (ja) 2007-09-19 2015-05-27 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー RNAiにおけるオフターゲット表現型の影響を減少させるためのSiRNA配列非依存性修飾フォーマットおよびその安定化型
NZ585327A (en) * 2007-11-26 2012-10-26 Santaris Pharma As Lna antagonists targeting the androgen receptor
US7863437B2 (en) * 2007-12-03 2011-01-04 Enzon Pharmaceuticals, Inc. RNA antagonist compounds for the modulation of PIK3CA expression
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2633052B1 (en) * 2010-10-27 2018-04-11 CuRNA, Inc. Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
HK1200484A1 (zh) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
CN104254610A (zh) * 2012-03-12 2014-12-31 桑塔里斯制药公司 调节atxn3表达的组合物和方法
CN104583402A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
EA201492120A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии atp2a2
JP2015523854A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Smn遺伝子ファミリー発現を調節するための組成物及び方法
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
CN104540946A (zh) 2012-05-16 2015-04-22 Rana医疗有限公司 用于调节utrn表达的组合物和方法
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
JP6429264B2 (ja) * 2013-11-12 2018-11-28 学校法人東京理科大学 ボラノホスフェート化合物、及び核酸オリゴマー
EP3083960B1 (en) 2013-12-16 2021-02-03 Syddansk Universitet Ras exon 2 skipping for cancer treatment
CA2975525A1 (en) 2015-02-04 2016-08-11 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
US20180023081A1 (en) * 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
ES2893114T3 (es) 2015-02-04 2022-02-08 Bristol Myers Squibb Co Métodos para seleccionar moléculas terapéuticas
WO2016130943A1 (en) * 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
US11306312B2 (en) * 2017-09-01 2022-04-19 Thomas Jefferson University Compositions and methods for MYC messenger RNA inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5935779A (en) * 1988-11-03 1999-08-10 Igen International Inc. Methods for improved particle electrochemiluminescence assay
US5962218A (en) * 1988-11-03 1999-10-05 Igen International Inc. Methods and apparatus for improved luminescence assays
EP0590082B1 (en) * 1991-06-14 1999-10-27 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
US5872242A (en) * 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
WO2001048190A2 (en) * 1999-12-23 2001-07-05 Exiqon A/S Therapeutic uses of lna-modified oligonucleotides
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
US20040241717A1 (en) * 2003-02-10 2004-12-02 Santaris Pharma A/S Oligomeric compounds for the modulation of thioredoxin expression

Similar Documents

Publication Publication Date Title
JP6626101B2 (ja) GalNAcホスホラミダイト、その核酸結合体およびそれらの使用
KR101878587B1 (ko) 올리고머 및 올리고머 접합체
US10041074B2 (en) Euchromatic region targeting methods for modulating gene expression
ES2509140T3 (es) Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm
JP7798836B2 (ja) B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
US10758558B2 (en) Hybrid oligonucleotides and uses thereof
EP3442983A1 (en) TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
US20150225722A1 (en) Methods for selective targeting of heterochromatin forming non-coding rna
CN104755621A (zh) 癌症治疗
JP2010505432A5 (cg-RX-API-DMAC7.html)
JP2010524486A (ja) β−カテニンを調節するためのRNAアンタゴニスト化合物
CN105247052A (zh) B-细胞cll/淋巴瘤11a(bcl11a)的寡核苷酸调节剂及其用途
EP3256590A1 (en) Targeting oligonucleotides and uses thereof to modulate gene expression
KR20190047025A (ko) 변형된 올리고뉴클레오티드 및 사용 방법
US20100249219A1 (en) Short rna antagonist compounds for the modulation of hif-1alpha
JP2021524277A (ja) Rtel1発現の調節用のオリゴヌクレオチド
JP2012529279A (ja) 新規の強力な抗apobアンチセンス化合物
JP2011505798A (ja) Mcl−1を調節するためのRNAアンタゴニスト化合物
JP2004526737A5 (cg-RX-API-DMAC7.html)
CN115485381A (zh) 以apoc3为靶点的反义核酸
EP4493694A1 (en) Modified gapmer oligomers and methods of use thereof
WO2018130583A1 (en) Antisense oligonucleotides for modulating nfkb1 expression
US20250115909A1 (en) Compounds for inhibiting amanzi
US20250115914A1 (en) Compounds for inhibition of il-1beta expression